(4R)-4-羟基-L-脯氨酸乙酯 | 61478-25-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (4R)-4-羟基-L-脯氨酸乙酯
• 英文名称: (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid ethyl ester
• 英文别名: (2S,4R)-ethyl 4-hydroxypyrrolidine-2-carboxylate；ethyl (2S,4R)-4-hydroxytetrahydro-1H-pyrrole-2-carboxylate；ethyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate
• CAS: 61478-25-9
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: JMHQESARJMGVCZ-RITPCOANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (4R)-4-羟基-L-脯氨酸乙酯 在 sodium hydroxide 、 氯化亚砜 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 生成 methyl (2S,4R)-4-amino-1-benzyl-4-methoxycarbonylprolinate
  参考文献：
  名称：

  Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): Identification of a new group III metabotropic glutamate receptor selective agonist

  摘要：

  A new family of mGlu receptor orthosteric ligands called APTCs was designed and synthesized using a parallel chemistry approach. Amongst 65 molecules tested on mGlu4, mGlu6 and mGlu8 subtypes, (2S,4S)-4-amino-1-[(E)-3-carboxyacryloyl]pyrrolidine-2,4-dicarboxylic acid (8a06-FP0429) has been shown to be a full mGlu4 agonist and a partial mGlu8 agonist. In addition, 8a06 was shown to be selective versus group I and II mGlu subtypes. A possible explanation for this efficacy difference is proposed by docking experiment performed with molecular model of the receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.062
• 作为产物：
  描述：

  N-Cbz-trans-4-hydroxy-L-proline ethyl ester 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 2.5h， 生成 (4R)-4-羟基-L-脯氨酸乙酯
  参考文献：
  名称：

  Synthesis of the Four Isomers of 4-Aminopyrrolidine-2,4-dicarboxylate:  Identification of a Potent, Highly Selective, and Systemically-Active Agonist for Metabotropic Glutamate Receptors Negatively Coupled to Adenylate Cyclase

  摘要：

  The four isomers of 4-aminopyrrolidine-2,4-dicarboxylate (APDC) were prepared and evaluated for their effects at glutamate receptors in vitro. (2R,4R)-APDC (2a), an aza analog of the nonselective mGluR agonist (1S,3R)-1-aminocyclopentane-1,3-dicarboxylate ((1S,3R)-ACPD, 1), was found to possess relatively high affinity for metabotropic glutamate receptors (mGluRs) (ACPD-sensitive [H-3]glutamate binding IC50 = 6.49 +/- 1.21 mu M) with no effects on radioligand binding to NMDA, AMPA, or kainate receptors up to 100 mu M. None of the other APDC isomers showed significant mGluR binding affinity, indicating that this interaction is highly stereospecific. Both 1 and 2a were effective in decreasing forskolin-stimulated cAMP formation in the adult rat cerebral cortex (EC(50) = 8.17 +/- 2.21 mu M for 1; EC(50) = 14.51 +/- 5.54 mu M for 2a); however, while 1 was also effective in stimulating basal tritiated inositol monophosphate production in the neonatal rat cerebral cortex (EC(50) = 27.7 +/- 5.2 mu M), 2a (up to 100 mu M) was ineffective in stimulating phosphoinositide hydrolysis in this tissue preparation, further supporting our previous observations that 2a is a highly selective agonist for mGluRs negatively coupled to adenylate cyclase. Microelectrophoretic application of either 1 or 2a to intact rat spinal neurons produced an augmentation of AMPA-induced excitation (95 +/- 10% increase for 1, 52 +/- 6% increase for 2a). Intracerebral injection of 1 (400 nmol) produced characteristic limbic seizures in mice which are not mimicked by 2a (200-1600 nmol, ic). However, the limbic seizures induced by 1 were blocked by systemically administered 2a in a dose-dependent manner (EC(50) = 271 mg/kg, ip). It is concluded that (2R,4R)-APDC (2a) is a highly selective, systemically-active agonist of mGluRs negatively coupled to adenylate cyclase and that selective activation of these receptors in vivo can result in anticonvulsant effects.

  DOI：

  10.1021/jm9601765

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013102242A1

  公开（公告）日：2013-07-11

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及吡咯烷和氮杂环丙烷化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。
• [EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
  申请人：NIMBUS LAKSHMI INC

  公开号：WO2017040757A1

  公开（公告）日：2017-03-09

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物用于抑制TYK2和治疗TYK2介导的疾病的方法。
• [EN] SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS<br/>[FR] COMPOSÉS DE SULFONAMIDE HÉTÉROCYCLIQUES SUBSTITUÉS UTILES COMME MODULATEURS DE TRPA1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015052264A1

  公开（公告）日：2015-04-16

  The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  本发明涉及式I或II的化合物及其盐。此外，本发明还涉及制备这些化合物的方法以及使用这些化合物的方法，以及含有这些化合物的药物组合物。这些化合物可能对治疗由TRPA1介导的疾病和状况，如疼痛，具有用途。
• Synthesis of Enantiopure Substituted Piperidines <i>via</i> an Aziridinium Ring Expansion
  作者：Scott B. D. Jarvis、Andre B. Charette

  DOI：10.1021/ol201349k

  日期：2011.8.5

  piperidines from readily available chiral building blocks. This method, which features a novel irreversible dihydropyrole-tetrahydropyridine ring expansion, allows the introduction of a large variety of substituents at the 3-position and permits substitution at the 2- and 6-position giving mono-, di-, or trisubstituted piperidines with high diastereocontrol.

  在这里，我们报道了一种新的方法，用于从容易获得的手性结构单元中不对称合成3取代的哌啶。该方法具有新颖的不可逆的二氢吡咯-四氢吡啶环扩环的特征，它允许在3位引入多种取代基，并允许在2位和6位取代，从而得到单，二或三取代的哌啶高非对映控制。
• [EN] AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE<br/>[FR] AMINOACIDE ET PEPTIDE CONJUGUÉS D'ACIDE ARYL-ALKYLE DESTINES A ETRE UTILISES EN COSMETIQUE
  申请人：DSM IP ASSETS BV

  公开号：WO2005092850A1

  公开（公告）日：2005-10-06

  The invention provides novel compounds of general formula (I), wherein R1, R2 and R3 are independently hydrogen, OR4, C1-C6 alkyl or C2-C6 alkenyl, R4 is hydrogen, C1-C6 alkyl or C2-C6 alkenyl, -N-(AA) represents the residue of an amino acid or of a peptide which is bonded over the N-terminus of the amino acid or the peptide and the peptide is composed of 2 to 6, that means 2, 3, 4, 5 or 6, amino acids, wherein the C-terminus of the amino acid or the peptide is optionally esterified with a C1-C16 hydrocarbon moiety and n is an integer of 1 to 5. The compounds are in particular useful for cosmetic applications.

  该发明提供了一般式（I）的新化合物，其中R1、R2和R3分别是氢、OR4、C1-C6烷基或C2-C6烯基，R4是氢、C1-C6烷基或C2-C6烯基，-N-(AA)代表氨基酸或肽的残基，该残基与氨基酸或肽的N-末端结合，该肽由2至6个氨基酸组成，即2、3、4、5或6个氨基酸，其中氨基酸或肽的C-末端可以选择性地与C1-C16烃基酯化，n是1至5的整数。这些化合物特别适用于化妆品应用。